Q1 Earnings Estimate for Belite Bio Issued By HC Wainwright

Belite Bio, Inc (NASDAQ:BLTE) – Research analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for shares of Belite Bio in a research note issued to investors on Tuesday, March 18th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.37) per share for the quarter, down from their previous estimate of ($0.32). HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio’s Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.46) EPS.

A number of other equities research analysts have also recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Belite Bio in a research note on Tuesday. Benchmark boosted their price target on Belite Bio from $57.00 to $79.00 and gave the company a “buy” rating in a report on Tuesday, January 21st.

Belite Bio Stock Performance

Shares of BLTE opened at $67.73 on Thursday. The stock has a fifty day moving average price of $59.24 and a two-hundred day moving average price of $60.71. Belite Bio has a 52-week low of $31.01 and a 52-week high of $86.53. The company has a market cap of $2.16 billion, a price-to-earnings ratio of -61.02 and a beta of -1.54.

Belite Bio (NASDAQ:BLTE) last released its earnings results on Monday, March 17th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02).

Institutional Investors Weigh In On Belite Bio

Hedge funds have recently modified their holdings of the company. Bank of America Corp DE raised its position in shares of Belite Bio by 36.4% in the 4th quarter. Bank of America Corp DE now owns 18,342 shares of the company’s stock worth $1,157,000 after acquiring an additional 4,891 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Belite Bio during the 4th quarter worth approximately $155,000. XTX Topco Ltd increased its holdings in Belite Bio by 30.9% during the 4th quarter. XTX Topco Ltd now owns 7,062 shares of the company’s stock worth $446,000 after purchasing an additional 1,668 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Belite Bio by 130.3% during the 4th quarter. JPMorgan Chase & Co. now owns 14,636 shares of the company’s stock worth $924,000 after purchasing an additional 8,280 shares in the last quarter. Finally, Advisors Preferred LLC bought a new stake in Belite Bio during the 4th quarter worth approximately $52,000. Institutional investors and hedge funds own 0.53% of the company’s stock.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.